Transplant News and Research

RSS

Gene Signal publishes phase I data on GS-101 for diseases of the eye

Gene Signal, a company focused on developing innovative drugs to manage angiogenesis based conditions, has announced publication of data from a phase I study demonstrating that the antisense oligonucleotide GS-101 (eye drops) is safe, with no signs of intolerability following administration to healthy volunteers.

11 Aug 2009

Genzyme updates on Cerezyme supply plus 2009 financials

Genzyme Corporation (NASDAQ: GENZ) today provided an update on the impact of Cerezyme® (imiglucerase for injection) supply constraints on patient treatment regimens and on the company’s 2009 financial results. The company’s Fabrazyme® (agalsidase beta) supply constraint period, Fabrazyme dose conservation guidelines for patients, and Fabrazyme financial guidance are unchanged.

11 Aug 2009

New molecule blocks lymphangiogenesis

Researchers in the laboratory of Dr. Jayakrishna Ambati at the University of Kentucky have discovered the first naturally occurring molecule that selectively blocks lymphatic vessel growth. In an article in the Aug. 9, 2009 online edition of Nature Medicine, they report the identification of a new molecule known as soluble VEGFR-2 that blocks lymphangiogenesis - the growth of lymphatics - but not blood vessel growth.

11 Aug 2009

Association of Specialty Professors announces the 2009 T. Franklin Williams scholars

The Association of Specialty Professors (ASP) is pleased to announce the eighth class of T. Franklin Williams Scholars. These scholars are recipients of two- to four-year career development awards funded by a generous grant from the Atlantic Philanthropies (USA) Inc. and the John A. Hartford Foundation, and co-sponsored by 12 internal medicine specialty societies.

10 Aug 2009

NIH stimulus funding supports Emory - grants to advance research, create jobs, support students

At least 50 research projects so far, supported by more than $10 million in stimulus grants from the National Institutes of Health, are expected to lead to new discoveries at Emory University that will improve medical treatment, create new jobs, and provide additional educational opportunities for students. Emory has received half of all the NIH ARRA grants awarded to Georgia academic institutions thus far.

9 Aug 2009

Soliris (Eculizumab) granted orphan drug designation in Europe and U.S. for atypical hemolytic uremic syndrome

Alexion Pharmaceuticals, Inc. has announced today that Soliris® (eculizumab), its first-in-class complement inhibitor, has been granted Orphan Medicinal Product Designation by the European Commission for the treatment of patients with atypical Hemolytic Uremic Syndrome (aHUS). AHUS is an ultra-rare, inherited, and life-threatening complement-inhibitor deficiency disease that often progresses to end-stage kidney disease or failure. The U.S. Food and Drug Administration granted orphan drug designation to Soliris for the same indication in May 2009. Soliris is not approved for the treatment of patients with aHUS.

6 Aug 2009

Complex, eight-hour open procedure removes life-threatening blood clots from 17-year-old's lungs

After visiting the emergency room with fainting spells and shortness of breath, a 17-year-old Morningside Heights boy was diagnosed with rare, life-threatening blood clots blocking his pulmonary arteries. To address the problem, surgeons at NewYork-Presbyterian Hospital Morgan Stanley Children's Hospital successfully performed a pulmonary thromboendartectomy (PTE) surgery -- reportedly, the first time it has been performed on a child in the New York City area.

6 Aug 2009

Thermogenesis expands collaboration with Celling Technologies

ThermoGenesis has announced an expanded collaboration with Celling Technologies, a subsidiary of SpineSmith, LLC, related to the Company's bone marrow products, MXP(TM) MarrowXpress(TM) and Res-Q(TM) 60 BMC. Celling is a leading distributor of orthopedic products, based in Texas.

6 Aug 2009

Phase 1 clinical trial starts for new antibody aimed at hepatitis C virus

Building upon a series of successful preclinical studies, researchers at MassBiologics of the University of Massachusetts Medical School (UMMS) today announced the beginning of a Phase 1 clinical trial, testing the safety and activity of a human monoclonal antibody they developed that can neutralize the Hepatitis C virus (HCV).

6 Aug 2009

Genzyme’s Mozobil approved in Europe

Genzyme Corporation announced today that the European Commission has granted marketing authorization for Mozobil ® (plerixafor injection), providing a significant new option for patients with the blood cancers lymphoma and multiple myeloma who require an autologous stem cell transplant.

6 Aug 2009

Discovery of new gene mutations linked to leukemia

Decoding the complete DNA of cancer patients is giving scientists at Washington University School of Medicine in St. Louis a clearer picture of the complexity of the disease and allowing them to see intriguing and unexpected genetic relationships among patients.

5 Aug 2009

Jefferson names endowed Professorship in transplant surgery

Cataldo Doria, M.D., Ph.D., F.A.C.S., director, Division of Transplant Surgery, in the Department of Surgery at Thomas Jefferson University Hospital, has been named the Nicoletti Family Professor of Transplant Surgery. This endowed professorship is a generous gift of Robert and Beatrice Nicoletti and their family. The family cited the care they received at Jefferson when Robert received a new kidney donated by his own daughter, as the reason for their donation.

4 Aug 2009

The extremes of BMI a cause for concern in liver transplantation

A recent study by doctors at the University of Washington explained that patients who are significantly underweight or very severely obese prior to liver transplantation are at increased risk of death following transplantation surgery.

4 Aug 2009

Hospital dramatically increases transplant donations by integrating bereavement and donor services

A UK hospital that combined its bereavement and donation services saw a forty-fold increase in tissue donations, such as corneas, in just five years, according to research in the August issue of Anaesthesia.

30 Jul 2009

Young binge drinker dies after he was refused a liver transplant

A 22 year old British man who was refused a liver transplant has died from cirrhosis of the liver after a binge-drinking habit which began when he was age 13.

22 Jul 2009

Skin cancer researchers throw new light on tumour growth

Three researchers from the Dermatology Research Foundation at the University of Sydney have identified a compound produced by certain fatal skin cancer tumours, providing new hope for developing treatments.

14 Jul 2009

Johns Hopkins leads first 16-patient, multicenter "domino donor" kidney transplant

Surgical teams at The Johns Hopkins Hospital, Barnes-Jewish Hospital in St. Louis, INTEGRIS Baptist Medical Center in Oklahoma City and Henry Ford Hospital in Detroit successfully completed the first eight-way, multihospital, domino kidney transplant. The transplant involved eight donors - 3 men and 5 women along with eight organ recipients - 3 men and 5 women. "All Johns Hopkins patients are in good condition and are recovering as anticipated," according to Robert A. Montgomery, M.D., Ph.D., director of the Johns Hopkins Comprehensive Transplant Center.

7 Jul 2009

Researchers profile genes in acutely ill idiopathic pulmonary fibrosis patients

The first findings from a one-of-a-kind, patient-driven effort to provide lung tissue for research might help doctors predict when patients with idiopathic pulmonary fibrosis (IPF) are becoming dangerously ill and also could point the way to interventions that could sustain them until life-saving transplants can be performed.

7 Jul 2009

Future of organ transplantation - microscopic beads that create "designer " immune cells

The future of organ transplantation could include microscopic beads that create "designer" immune cells to help patients tolerate their new organ, Medical College of Georgia researchers say.

6 Jul 2009

Women with cystic fibrosis can have safe and successful fertility treatment

Women with cystic fibrosis can have fertility treatment to help them have babies without any long-term adverse effects on either themselves or their children, according to new research presented at the 25th annual meeting of the European Society of Human Reproduction and Embryology in Amsterdam today (Tuesday).

30 Jun 2009